TLDR
- MRNA hit a 52-week high of $81.42, up 169.2% over the past year
- The stock has gained 124% in just the past six months
- InvestingPro flags the stock as overvalued vs its Fair Value estimate
- Analysts maintain an average “Reduce” rating with a mean price target of $37.13
- Insiders have sold 125,088 shares worth over $6.1 million in the last 90 days
Moderna stock touched $81.42 on July 6, setting a new 52-week high and extending one of the more eye-catching runs in biotech this year. The stock was trading around $81.51 shortly after, giving the company a market cap of roughly $32.2 billion.
The 52-week low sits at $22.28. That means MRNA has more than tripled off its bottom over the past year — a 169.2% gain in total.
The six-month surge alone clocks in at 124%, driven in part by renewed interest in Moderna’s mRNA platform and a string of pipeline updates.
At its Science Day event, Moderna revealed that its in vivo CAR-T program, mRNA-6007, is moving into early development for autoimmune diseases, with a focus on systemic lupus erythematosus and other B cell-mediated conditions.
The FDA also played a role. An advisory committee unanimously recommended Moderna’s investigational seasonal flu vaccine, mRNA-1010, for adults 50 and older — a clean win for the pipeline story.
Options traders took notice. Volume hit 121,257 contracts, with notable activity on the June 18, 2026 $65 call.
Analysts Aren’t Buying the Rally
Despite the price action, the analyst community is not exactly celebrating. Moderna carries an average rating of “Reduce” with a mean price target of just $37.13 — less than half where it’s currently trading.
Goldman Sachs raised its target from $43 to $49 with a “neutral” rating. Bank of America went from $32 to $34 but kept an “underperform.” Barclays moved from $25 to $48 with “equal weight.” Jefferies and UBS both reiterated “hold.”
Of the analysts covering MRNA, two rate it a Buy, eleven a Hold, and five a Sell.
InvestingPro data places the stock among the most overvalued on the platform relative to its Fair Value estimate.
Insiders Are Heading for the Exit
While institutions have been adding, insiders have been selling. Director Abbas Hussain sold 5,682 shares at $46.63 on May 1, cutting his ownership by 32%. Director Noubar Afeyan sold 9,263 shares at $46.84 on May 21, reducing his stake by 70.24%.
In total, insiders have sold 125,088 shares worth over $6.1 million in the past 90 days. Insiders now own 10.80% of the company.
On the institutional side, the picture is more positive. Louisiana State Employees Retirement System initiated a new position of 17,700 shares worth around $899,000 in Q1. AQR Capital, NewEdge Advisors, and American Century Companies also added exposure. Institutions now own 75.33% of MRNA.
The most recent earnings report, released May 1, showed Q1 revenue of $389 million — up 260.2% year-over-year and well above the $236.37 million estimate. EPS came in at -$3.40, missing the consensus of -$3.02. The company’s 50-day moving average sits at $53.50, its 200-day at $48.22.
4th of July Flash Sale – 50% OFF!
Celebrate Independence Day by investing in your future. For a limited time, get 50% OFF a Knockout Stocks membership and unlock our latest high-conviction stock picks, powered by our proprietary KO Score algorithm.
You'll also get access to our long-term investment ideas and shorter-term trade opportunities, helping you identify potential opportunities before the crowd.
Sign up to Knockout Stocks today and get 50% OFF to unlock the full list of premium stock picks.
Use coupon code SPECIAL50 for your exclusive discount.
Offer ends soon. Don't miss out!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
